ClinicalTrials.gg
TerminatedNCT00945646Updated May 27, 2021

FST-201 In The Treatment of Acute Fungal Otitis Externa

A Phase 3 interventional study of FST-201 (dexamethasone 0.1%) Otic Suspension and Vehicle in Acute Fungal Otitis Externa, sponsored by Shire. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-27.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the efficacy of FST-201 compared to vehicle in the treatment of acute fungal otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute fungal otitis externa.

02

Conditions studied

  • Acute Fungal Otitis Externa

Browse trials for

03

In context

Otitis Externa

22 studies on the registry are indexed under Otitis Externa; 1 is open to participants now.

This study's enrollment of 6 is below the median of 100 across 20 interventional studies indexed under Otitis Externa.

Browse Otitis Externa studies →

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of AFOE of in one or both ears, based on a clinical score of at least 1 for edema (0-3 scale), 2 for overall inflammation (0-3 scale) and 1 for tenderness (absent=0, present=1) and/or 1 for pruritis (absent = 0, present = 1)
  • Have appearance consistent with fungal debris, i.e. white or black appearance consistent with Aspergillus spp. or Candida spp.
  • Be at least 18 years of age at Visit 1 (Day 1, Screening/Baseline) of either sex and any race
  • Provide written
  • Be willing and able to follow all instructions and attend all study visits
  • If female and of child bearing potential, agree to and submit a urine sample for pregnancy testing at Visit 1 and upon their exit from the study. Post menopausal is defined as having no menses for 12 consecutive months.

Exclusion criteria

Exclusion Criteria:

  • Have known sensitivity to any component of the study medications
  • Have a current infection requiring systemic antimicrobial treatment
  • Take any systemic (within 30 days) or otic (within 1 day) prior to Visit 1
  • Have used topical or systemic anti-inflammatory agents on the same day as Visit 1 and for the duration of the study
  • Have used topical or systemic pain medications on the same day as Visit 1 and for the duration of the study
  • Have used any topical otic treatment within 1 days prior to Visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    FST-201 (dexamethasone 0.1%) Otic Suspension

    Drug: FST-201 (dexamethasone 0.1%) Otic Suspension

  • Placebo comparator
    vehicle

    Drug: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Overall clinical cure as defined by absence of the signs and symptoms of AFOE including ear inflammation, edema, tenderness, pruritis and otic discharge.

    Time frame: 1 year

Secondary outcomes

  1. Microbiological resolution defined as absence of pre-treatment pathogenic fungal species.

    Time frame: 1 year

07

Study locations

6 sites
  • ENT Associates of South Florida
    Boynton Beach, Florida 33426, United States
  • Sarasota, Florida 34239, United States
  • Austin Ear, Nose, and Throat Clinic
    Austin, Texas 78705, United States
  • San Antonio Ear, Nose, and Throat Research
    San Antonio, Texas 78215, United States
  • San Antonio Ear, Nose, and Throat Research
    San Antonio, Texas 78229, United States
  • Ear Institute of Texas
    San Antonio, Texas 78258, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2009 to primary completion in Jul 2010, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2009
First posted
Jul 24, 2009
StartActual
Jul 31, 2009
Primary completionActual
Jul 31, 2010
CompletionActual
Jul 31, 2010
Results delay requested
Sep 5, 2012
Last update
May 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00945646
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 24, 2009
Start date
Jul 31, 2009
Primary completion
Jul 31, 2010
Completion
Jul 31, 2010
Last update
May 27, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion